Close Menu

NEW YORK (GenomeWeb) – GenDx announced today that it has received IVD marking from South Korean regulators for its NGSgo human leukocyte antigen (HLA) typing workflow used in transplant medicine.

According to the company, the workflow is now cleared by the South Korean Ministry of Food and Drug Safety for the typing of HLA-A, B, C, DRB1, and DQB1 by next-generation sequencing on Illumina Miseq platforms, followed by analysis with GenDx's NGSengine software.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.